RS
PRME icon

R Squared’s Prime Medicine PRME Stock Holding History

R Squared’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,519
Closed -$30.9K – 675
2025
Q2 		$30.9K Buy
+12,519
New +$19.3K 0.02% 420
2025
Q1 		– Sell
-2,230
Closed -$6.51K – 1192
2024
Q4 		$6.51K Buy
+2,230
New +$7.83K 0.01% 1260

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

R Squared's PRME Position: Q3 2025 in Review

R Squared sold out of Prime Medicine (PRME) in Q3 2025, closing a stake of 12,519 shares — an estimated $30.9K sold.

R Squared first reported a position in PRME in Q4 2024 and held it in 2 quarters. The position peaked at $30.9K in Q2 2025. 167 funds tracked by Wall St. Rank hold PRME as of Q3 2025.

  • R Squared reported no remaining Prime Medicine position as of Q3 2025 after selling out during the quarter.
  • R Squared sold 12,519 Prime Medicine shares in Q3 2025, an estimated $30.9K.
  • R Squared first reported a position in Prime Medicine in Q4 2024 and held it in 2 quarters.
  • R Squared's Prime Medicine position peaked at $30.9K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.